Business
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the next stage of growth NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the sale, for $400 million, of an additional 25% of the company’s royalty interest from Kyowa Kirin Co., Ltd on the future sales of Crysvita® (burosumab) in the United States (U.S.) and Canada to OMERS, one of Canada’s largest defined benefit pension plans. OMERS will receive the additional 25% royalty interest on net sales of Crysvita® beginning in January 2028. Pursuant to the new agreement, OMERS will also continue to receive 30% of Crysvita® net sales in the U.S. and Canada following the achievement of the 2022 royalty purchase agreement transaction's cap of 1.45 times the purchase price. Total payments to OMERS pursuant to the new agreement are capped at 1.55 times the purchase price. “Crysvita continues its strong growth trajectory, treating more than 3,000 patients and generating greater than $4 billion of cumulative U.S. and Canada sales since launching over seven years ago. The cash from this financing and the payment holiday through January 2028 bolsters our balance sheet to help us deliver on our expected launches and our path to full year GAAP profitability in 2027,” said Howard Horn, chief financial officer and executive vice president, corporate strategy of Ultragenyx. “Building on our 2022 transaction, OMERS again offered the most attractive financial package and cost of capital, and we are pleased to expand our relationship with them.” “Ultragenyx has been an outstanding partner and a leader in the rare disease space for over a decade. Crysvita has made a difference in the lives of thousands of pediatric and adult patients with rare bone diseases and we are proud to expand our investment in this growing product,” said Rob Missere, managing director and head of life sciences at OMERS. “This deal closely aligns with our life sciences investment strateg...